We’re excited to share updated translational data from our Phase 1 AMPLIFY-7P study at #SITC24 during Friday’s poster session (Abstract #1473). Read more: elicio.com/press_releases…

Preprint alert! New preclinical data from our team shows that AMP-engineered DNA adjuvants can trigger a robust type I interferon response in mouse and NHP lymph nodes—demonstrating their potential to enhance both cellular and humoral immunity in vaccines. biorxiv.org/content/10.110…

We're excited to announce that we've completed enrollment in our Phase 2 AMPLIFY-7P study. Read more in our latest PR: elicio.com/press_releases…

Earlier today we shared updated Phase 1 data from our AMPLIFY-201 clinical trial at the ESMO Immuno-Oncology Congress 2024.  Read more in the full release: elicio.com/press_releases…

Today we announced that we've reached alignment with the FDA on the registrational study strategy for our lead candidate ELI-002—a novel AMP cancer vaccine targeting mKRAS-driven cancers. Read more: elicio.com/press_releases…

We’re thrilled to welcome Preetam Shah to the Elicio team as our new Chief Strategy and Financial Officer! Read more: elicio.com/press_releases…

Today we're excited to share our 2024 financial results and corporate updates. Read the release:  elicio.com/press_releases…

Elicio Therapeutics today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate and clinical updates. Read more: bit.ly/44w276G $ELTX

Robert Connelly, CEO of Elicio, comments on the Company's progress towards the upcoming Phase 2 AMPLIFY-7P event-driven interim analysis expected in Q3 2025. For recent highlights and upcoming anticipated milestones, visit: bit.ly/44w276G $ELTX

Our lymph node-targeted platform aims to amplify the body's immune response to defeat solid tumors, with a focus on pancreatic ductal adenocarcinoma (PDAC). Visit the Elicio website to learn more: bit.ly/3T1D0Sa $ELTX

Elicio Therapeutics Secures $10 Million in Financing bit.ly/3SCy32a $ELTX

With a focus on pancreatic ductal adenocarcinoma (PDAC), Elicio is advancing immunotherapies built to target the lymphatic system and amplify anti-tumor responses. Learn more about our pipeline: bit.ly/4kldaEC $ELTX

We develop next-gen vaccines, immunomodulators, and adjuvants, built with our lymph node-targeting Amphiphile (AMP) platform. Our goal is to defeat the most challenging cancers, with a focus on pancreatic ductal adenocarcinoma (PDAC). Learn more: bit.ly/43qUc9U $ELTX

At Elicio, we are developing cancer immunotherapies designed to harness the natural power of our immune system. Follow us for the latest updates on our pipeline and clinical progress: bit.ly/3T1D0Sa $ELTX

Elicio will host a KOL event on Wednesday, June 25th at 2:00 PM ET to discuss the significant unmet need and current treatment landscape for mutant-KRAS driven PDAC, one of the most lethal and underserved solid tumors. Register here: bit.ly/4n4wtnu $ELTX

Tune-in on Wednesday, June 25th at 2 PM ET for Elicio's KOL event on AMP-powered ELI-002 for the treatment of mutant-KRAS driven PDAC. The event will feature insights from leading experts Darrell Irvine, PhD and Eileen M O’Reilly. Register here: bit.ly/4n4wtnu $ELTX

Our Amphiphile (AMP) platform delivers therapeutic payloads directly to the lymph nodes to enhance the cancer-fighting mechanisms of the immune system. See how we intend to harness our AMP platform to defeat difficult-to-target cancers: bit.ly/43qUc9U $ELTX

Today at 2:00 PM ET: Hear Darrell Irvine, Ph.D discuss the challenges with cancer vaccines and provide an overview of Elicio's AMP platform, and Eileen M O’Reilly, on the significant unmet need and treatment landscape for mutant-KRAS driven PDAC. bit.ly/4n4wtnu $ELTX

Our KOL event on AMP-powered ELI-002 for mutant-KRAS driven pancreatic cancer, featuring Darrell Irvine, Ph.D. (The Scripps Research Institute & HHMI) and Eileen O’Reilly, M.D. (Memorial Sloan Kettering), is now available. Watch the replay here: bit.ly/4n4wtnu $ELTX

Our Virtual KOL Event is now available for replay! Watch the full discussion to hear insights on our lymph node–targeting Amphiphile (AMP) platform and the treatment landscape for mutant-KRAS driven pancreatic cancer: bit.ly/4n4wtnu $ELTX